ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019
Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Design and synthesis of butyrolactone V derivatives and its anti-inflammatory activity analysis.Chinese herbal medicines · 2026Article
- Emerging gut microbial glycoside hydrolase inhibitors.RSC chemical biology · 2025Review
- Electroacupuncture relieves type 2 diabetes by regulating gut microbiome.World journal of diabetes · 2025Article
- Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1.MedComm · 2025Article
- Butyrolactone-I from Marine Fungal Metabolites Mitigates Heat-Stress-Induced Apoptosis in IPEC-J2 Cells and Mice Through the ROS/PERK/CHOP Signaling Pathway.Marine drugs · 2024Article
- Natural Products from Marine-Derived Fungi with Anti-Inflammatory Activity.Marine drugs · 2024Review
- Alteration in gut mycobiota of patients with polycystic ovary syndrome.Microbiology spectrum · 2023Article
- Deciphering Molecular Aspects of PotentialMetabolites · 2023Article
- Targeting the human gut microbiome with small-molecule inhibitors.Nature reviews. Chemistry · 2023Review
- A Single Strain ofNutrients · 2023Article
- The molecular link between obstructive sleep apnea and osteoarthritis: based on bioinformatics analysis and experimental validation.American journal of translational research · 2023Article
- Inflammatory Mechanisms of Diabetes and Its Vascular Complications.Biomedicines · 2022Review
- Tang-Ping-San Decoction Remodel Intestinal Flora and Barrier to Ameliorate Type 2 Diabetes Mellitus in Rodent Model.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Electroacupuncture at Lower He-Sea and Front-Mu Acupoints Ameliorates Insulin Resistance in Type 2 Diabetes Mellitus by Regulating the Intestinal Flora and Gut Barrier.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Improvement of intestinal barrier function, gut microbiota, and metabolic endotoxemia in type 2 diabetes rats by curcumin.Bioengineered · 2021Article
- A Review of the Pharmacological Activities and Recent Synthetic Advances of γ-Butyrolactones.International journal of molecular sciences · 2021Review
- Coral-Derived Endophytic Fungal Product, Butyrolactone-I, Alleviates Lps Induced Intestinal Epithelial Cell Inflammatory Response Through TLR4/NF-κB and MAPK Signaling Pathways: AnFrontiers in nutrition · 2021Article
- Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.Marine drugs · 2020Article
- Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the effects of butyrolactone-I (A6) on type 2 diabetes (T2D) in db/db mice because A6 was found to inhibit α-glucosidase activities and TNF-α release, which were associated with improving T2D. Male db/db mice were divided into 6 groups and given an equivalent volume of olive oil, acarbose, or different doses of A6 for 4 wk (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.